Bayer's Trasylol Increases Risk Of Death: Study

Law360, New York (June 2, 2008, 12:00 AM EDT) -- Just weeks after Bayer AG yanked the leftover stock of its blood-clotting drug Trasylol from the U.S. market, a newly published study has revealed that patients receiving the drug have a greatly increased risk of death.

The final results of the long-awaited study, published last Thursday in the New England Journal of Medicine, showed that Trasylol increases the risk of death by 54% while also greatly increasing the risk of other heart complications.

Bayer suspended sales of Trasylol in November at the urging of the U.S....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.